Related Experiment Video
Updated: Jun 10, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
High-dose rate brachytherapy in prostate cancer patients--a study on nausea and vomiting
1Clinical Support Unit, St. Vincent's Private Hospital, Sydney Australia.
Abstract:
High-dose rate brachytherapy (HDRB) is one of many treatments for prostate cancer. Despite a reported 80% to 90% success rate in terms of cure rates, nausea and vomiting have been noted as a significant problem. At St. Vincent's Private Hospital, an incidence of nausea and vomiting was estimated at 67% of patients undergoing HDRB. This study examines the possible causes and risk factors of post-operative nausea and vomiting with this treatment option.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
